Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to shrink stubborn lung tumors in patients with rare mutations

NCT ID NCT06043817

Recruiting now Disease control Sponsor: Pierre Fabre Medicament Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 21 times

Summary

This study tests an experimental drug, STX-721, in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if it can shrink tumors. About 251 adults whose cancer has spread or cannot be removed by surgery will take the pill daily. The drug is designed to block signals that help these cancer cells grow.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHA Bundang Medical Center, CHA University

    RECRUITING

    Seongnam-si, 13496, South Korea

  • Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30

    RECRUITING

    Berlin, 12203, Germany

  • Chungbuk National University Hospital

    RECRUITING

    Cheongju-si, 28644, South Korea

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • City of Hope

    RECRUITING

    Huntington Beach, California, 92648, United States

  • City of Hope

    RECRUITING

    Irvine, California, 92618, United States

  • EDOG Institut de Cancerologie de l'Ouest - PPDS

    RECRUITING

    Saint-Herblain, Loire-Atlantique, 44115, France

  • Gustave Roussy

    RECRUITING

    Villejuif, 94800, France

  • Hospital Regional Universitario de Malaga - Hospital General

    RECRUITING

    Málaga, Malaga, 29010, Spain

  • Hospital Universitario Ramon y Cajal

    RECRUITING

    Madrid, 28034, Spain

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, 41013, Spain

  • Institut Claudius Regaud - PPDS

    RECRUITING

    Toulouse, 31059, France

  • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

    RECRUITING

    Barcelona, 8035, Spain

  • Levine Cancer Institute - Charlotte

    RECRUITING

    Charlotte, North Carolina, 28204-2990, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031-2171, United States

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 10002, Taiwan

  • Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis

    RECRUITING

    Amsterdam, 1066, Netherlands

  • SCRI Oncology Partners - PPDS

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11217, Taiwan

  • Thomas Jefferson University Research Facility

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030-4009, United States

  • University of Utah - Huntsman Cancer Institute - PPDS

    RECRUITING

    Salt Lake City, Utah, 84112-5550, United States

  • Universitätsklinikum Carl Gustav Carus an der TU Dresden

    RECRUITING

    Dresden, 01307, Germany

Conditions

Explore the condition pages connected to this study.

EGFR/HER2 EXON 20 INSERTION MUTATION NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER NSCLC